These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8225 related articles for article (PubMed ID: 23431672)

  • 1. A model for cutaneous squamous cell carcinoma in vemurafenib therapy.
    Kent R; Glorioso S; Nordberg ML
    J La State Med Soc; 2012; 164(6):311-3. PubMed ID: 23431672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vemurafenib (Zelboraf) in the therapy of melanoma].
    Liszkay G
    Magy Onkol; 2013 Jun; 57(2):110-3. PubMed ID: 23795356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
    Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
    J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous side effects of vemurafenib: a case report and discussion.
    Shea SM; Boyd K; Patterson J
    Wien Med Wochenschr; 2013 Aug; 163(15-16):376-9. PubMed ID: 23824179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
    Sibaud V; Lamant L; Maisongrosse V; Delord JP
    Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
    Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
    Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
    Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous adverse events during vemurafenib therapy.
    Chandrakumar SF; Yeung J
    J Cutan Med Surg; 2014; 18(4):223-8. PubMed ID: 25008438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of dermatologic events in vemurafenib-treated patients with melanoma.
    Lacouture ME; Duvic M; Hauschild A; Prieto VG; Robert C; Schadendorf D; Kim CC; McCormack CJ; Myskowski PL; Spleiss O; Trunzer K; Su F; Nelson B; Nolop KB; Grippo JF; Lee RJ; Klimek MJ; Troy JL; Joe AK
    Oncologist; 2013; 18(3):314-22. PubMed ID: 23457002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy.
    Yin VT; Wiraszka TA; Tetzlaff M; Curry JL; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2015; 31(4):e112-5. PubMed ID: 24833447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary cutaneous small/medium CD4+ T-Cell lymphoma occurring during treatment with vemurafenib for advanced melanoma.
    Garrido MC; Riveiro-Falkenbach E; Ruano Y; Ortiz P; Rodriguez-Peralto JL
    Am J Dermatopathol; 2015 Jun; 37(6):440-3. PubMed ID: 25357018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
    Chu EY; Wanat KA; Miller CJ; Amaravadi RK; Fecher LA; Brose MS; McGettigan S; Giles LR; Schuchter LM; Seykora JT; Rosenbach M
    J Am Acad Dermatol; 2012 Dec; 67(6):1265-72. PubMed ID: 22609219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eruptive squamous cell carcinomas after vemurafenib therapy.
    Mays R; Curry J; Kim K; Tsai K; Arora A; Khan F; Ramirez-Fort M; Ciurea A
    J Cutan Med Surg; 2013; 17(6):419-22. PubMed ID: 24138980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug safety evaluation of vemurafenib in the treatment of melanoma.
    Tsai KY; Nowroozi S; Kim KB
    Expert Opin Drug Saf; 2013 Sep; 12(5):767-75. PubMed ID: 23800008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vemurafenib-related cutaneous side effects ameliorated by acitretin.
    Chon SY; Sambrano BL; Geddes ER
    J Drugs Dermatol; 2014 May; 13(5):586-8. PubMed ID: 24809883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 412.